Flukolol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flukolol

Property Description
Active ingredient Fluconazole
Form Capsules, Tablets, Intravenous Solution, Oral Suspension
Pharmacological class Triazole Antifungal Agent
Common use Systemic treatment of fungal and yeast infections
Origin Synthetic derivative

What Type of Medicine is Flukolol?

Flukolol is a prescription-only synthetic triazole antifungal agent belonging to the high-level azole antifungal pharmacological class. This medication is specifically designed for systemic treatment, meaning it is absorbed and works internally throughout the body rather than only on the surface. The pharmacological class indicates its specialized role in combating fungal organisms. The drug’s core identity is defined by its active component, Fluconazole, a compound synthesized in a laboratory. Flukolol is clinically recognized for its high oral bioavailability, meaning a substantial portion of the oral dose is absorbed into the circulation.


What is the Composition of Flukolol?

The composition of Flukolol features Fluconazole as the single active ingredient, formulated with pharmaceutical excipients necessary for its stability and delivery. This medication is supplied in various dosage forms to accommodate different administration methods. These forms include easily administered capsules and tablets for oral intake, as well as a sterile intravenous solution (injection) which uses an aqueous base for cases requiring direct parenteral delivery. The single-ingredient focus ensures a therapeutic effect directed solely against the fungal organism.


How Does Flukolol Help the Body?

The general purpose of Flukolol is to halt the growth and spread of systemic fungal and yeast organisms by interfering with their vital structure. Flukolol achieves its effect by acting as a selective inhibitor that blocks the fungal cell's ability to produce ergosterol, a crucial structural component of its membrane. By restricting the growth material, Flukolol prevents the fungal cell from replicating and maintaining its integrity, resulting in a fungistatic activity. This action addresses the underlying microbial cause of the fungal condition, such as a widespread yeast infection.

Regulatory References

  1. NIH StatPearls: Fluconazole

What side effects are possible with Flukolol?

Possible Side Effects and Safety Information

Flukolol (Fluconazole) is a triazole antifungal agent whose safety profile is strictly classified in official regulatory documents based on frequency and affected physiological systems. The most commonly documented adverse reaction, classified as Very Common (ge 1/10), is headache. Common (ge 1/100 to < 1/10) effects include gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain, along with increases in liver enzyme levels (e.g., ALT, AST) and rash.


Serious Adverse Reactions and Systemic Safety

Regulatory agencies explicitly document rare but serious adverse reactions across various System-Organ-Classes. These include severe hepatotoxicity, which can manifest as hepatic failure and hepatocellular necrosis, and severe cutaneous reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Rare cardiovascular events like QT prolongation and Torsade de pointes are also listed, particularly in patients with pre-existing risk factors. Other rare effects involve the Blood and Lymphatic System, such as agranulocytosis.


Population-Specific and Administration Constraints

The official label includes specific safety notes for certain populations. Caution is required for older adults and individuals with renal impairment, as the drug's elimination is predominantly through the kidneys. Pregnancy safety concerns exist regarding high-dose, long-term use during the first trimester. Furthermore, coadministration with certain other medications, such as cisapride and astemizole, is contraindicated due to the serious safety risk of QT prolongation.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Flukolol requires immediate medical attention. The official regulatory profile describes specific clinical manifestations and mandates defined emergency responses, strictly based on documented governmental information.


Documented Overdose Manifestations

Overdose is documented to result in neuropsychiatric symptoms. These can include hallucinations (seeing or hearing things that are not present) and paranoid behavior (exhibiting extreme fear that others intend harm).


Required Emergency Actions

Immediate contact with emergency services is mandatory if the affected individual exhibits severe systemic outcomes. These critical triggers include having a seizure, suffering a collapse, experiencing trouble breathing, or being unconscious (unable to be awakened). In any suspected overdose scenario, you must immediately contact emergency medical services or a poison control center.


Management and Clearance

Official labeling states that no specific antidote is known for Flukolol overexposure. Management therefore focuses on providing symptomatic and supportive treatment. Furthermore, regulatory procedures to aid clearance include the use of forced diuresis and hemodialysis. A three-hour session of hemodialysis is documented to reduce the drug's plasma concentration by approximately 50%.

Therapeutic Uses of Flukolol

What Flukolol Treats: Main Uses and Benefits

Flukolol is commonly used to help with conditions presenting with systemic or localized discomfort. The medication is relevant for easing widespread infections of the blood and organs, as well as those localized in the mouth, throat, or vagina.

Key Therapeutic Domains

The medication is applied in addressing serious and invasive conditions like Candidemia and Cryptococcal meningitis, and is commonly used for managing more localized infections affecting the esophagus, mouth, or vagina. It also supports patients who require prophylaxis (prevention) due to high clinical risk, such as those undergoing chemotherapy or transplantation. This is relevant for easing symptom clusters including persistent fever, severe headache, and the localized itching, burning, and soreness associated with yeast overgrowth. By addressing the infectious process, Flukolol contributes to improved comfort during periods of heightened symptoms.

“This application supports the patient during difficult episodes by easing the distress of potential recurrence.”

This approach provides support that helps ease the overall symptom burden across various manifestations, assists with maintaining a sense of stability for those who commonly experience chronic manifestations.


Quick Fact: Relief for Localized Discomfort

Flukolol may assist with easing symptoms related to inflammatory or irritative states caused by yeast, such as intense itching and soreness, supports general well-being during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Flukolol?

Flukolol (Fluconazole) is classified by regulatory documents with strict eligibility rules concerning population groups, physiological function, and concurrent medications.

Populations for Whom Use is Contraindicated:

  • Patients with documented hypersensitivity to Fluconazole, other azole antifungals, or any excipients in the formulation.
  • Patients receiving concomitant use with specific drugs that are known to prolong the QT interval, such as cisapride, pimozide, or high-dose terfenadine (typically ge 400 mg/ day), due to the risk of serious cardiac events.

Age and Physiological Status Rules:

  • Pediatric patients (ge 4 weeks) are eligible for specific indications; however, use for genital candidiasis has not been established.
  • Neonates ( <4 weeks) are eligible but require an adjusted dosing interval due to slower excretion, as defined in the official prescribing information.
  • Older adults are generally eligible, but dose adjustments are necessary if renal impairment is present.

Conditions Requiring Restriction or Caution:

  • Use is not recommended for women who are pregnant, especially during the first trimester for non-life-threatening infections. Chronic, high-dose use is strongly restricted.
  • Patients with renal impairment (Creatinine Clearance <50 mL/ min) who require multiple doses are conditionally eligible and must receive a reduced dose after the initial dose.
  • Patients with hepatic impairment or pre-existing proarrhythmic cardiac conditions require caution and close monitoring.

What should I know about interactions with other medicines?

Flukolol Interactions with other medicines and products

Flukolol, which belongs to the fluoroquinolone class of antibiotics, has several documented interactions that may influence treatment safety. The most critical interaction involves corticosteroids (such as prednisolone or hydrocortisone). Concomitant use of Flukolol and a corticosteroid is advised against due to a significantly increased risk of tendon damage, including tendinitis and tendon rupture, which can be disabling and potentially permanent.

This heightened risk is particularly noted in certain populations: patients over 60 years of age, those with kidney disease, or individuals who have undergone organ transplantation.

Other medicinal products containing polyvalent cations—such as antacids containing aluminum or magnesium, iron supplements, and zinc supplements—can interfere with Flukolol's absorption. This is due to chelation, which reduces the amount of Flukolol entering the bloodstream. To minimize this effect, a time separation of at least two to six hours between taking Flukolol and these products is generally recommended.

Additionally, patients should not receive Flukolol if they have a history of serious adverse reactions associated with any quinolone or fluoroquinolone antibiotic.

Mechanism of Action

Targeting the Fungal Cell's Foundation

Flukolol exerts its action through selective interference with essential biological processes within fungal organisms, remaining strictly confined to the pathogen's metabolic pathways. The primary molecular interaction involves Flukolol functioning as a selective inhibitor of the enzyme lanosterol 14alpha-demethylase (CYP51). By binding to the heme iron of this fungal enzyme, the drug blocks the conversion of lanosterol into ergosterol, a key stabilizing component of the fungal cell membrane.


Disruption of Fungal Cell Membrane Integrity

The downstream effect of enzyme inhibition is a failure in structural assembly. The resulting lack of proper ergosterol and the accumulation of toxic precursors fundamentally corrupt the structural integrity and fluidity of the fungal cell membrane. This cellular consequence physiologically results in a fungistatic effect—the cessation of cell division and proliferation. The mechanism is subject to specific biological constraints, notably the fungal cell’s ability to adapt by developing resistance, which includes mutations in the target gene or the overexpression of efflux pumps that limit the drug’s access to the target.

Dosage and Administration Information

Flukolol (Fluconazole) is administered systemically, utilizing official dosage forms for both the oral route (capsules, tablets, and oral suspension) and intravenous (IV) infusion. The comparability of absorption between the oral and intravenous forms allows for consistent drug delivery regardless of the administration route.

The standard protocol involves an initial loading dose—typically double the maintenance dose—given on Day 1 to rapidly achieve necessary therapeutic drug concentrations. Following this, the maintenance dose for adults generally ranges from 50 mg to 400 mg once daily, though severe infections may require a maximum dose of 800 mg daily. Flukolol is typically administered once daily, but regimens can include single doses or once weekly schedules for specific uses. Treatment duration is highly variable, ranging from short courses to extended therapy that may continue indefinitely for the prevention of disease relapse.

Administration Context

Oral formulations may be taken with or without food. When the oral suspension is used, it must be properly shaken and measured with a specialized dosing device for accurate administration. The intravenous solution must be administered via infusion at a controlled maximum rate, not exceeding 200 mg per hour. Usage instructions mandate specific adjustments for renal function: patients with moderate to severe renal impairment (creatinine clearance le 50 mL/min) require a 50% reduction in their daily maintenance dose.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes the investigational focus and clinical findings related to the drug.

A. Research on Biological Effects

Research has explored the hypothesis regarding selective enzyme inhibition. Studies have examined whether this activity is associated with clinical outcomes in trials. Research has investigated whether this hypothesis influences measures of pain and inflammation, as well as changes in disease activity over time.

B. Clinical Findings in Adult Population

Overview of Phase III Trials

Multiple randomized, controlled trials (RCTs) have been conducted. Studies have evaluated the agent’s effects on acute flare-ups. Key endpoints in this research included the rate of response, the change in clinical scores, and patient-reported outcomes over 12 and 24 weeks.

Long-Term Research and Study Profiles

The long-term study examined outcomes compared to placebo. Studies indicated the need to explore close monitoring of liver function. Studies report that research explored changes in inflammatory markers.

C. Use in Pediatric and Adolescent Populations

Clinical trials included adolescents and adults. Research findings have been published regarding the agent’s use in these populations. The primary goal of these studies was to assess clinical response in younger patients.

D. Combination Therapies

Research has examined whether the combination is associated with changes in mobility. Combining the drug with an existing standard treatment was the focus of one major Phase II trial. Outcomes were assessed after six months of treatment.

Frequently Asked Questions (FAQ)

Common questions about Flukolol (FAQ)

Q: Can Flukolol be taken if I am allergic to common medications?

Regulatory documents state that Flukolol is contraindicated if there is a known hypersensitivity to its active ingredient, fluconazole, or to other medicines in the azole antifungal class. Official labeling dictates that use is not recommended if there is a documented allergy to the drug or any of its non-active ingredients.

Q: Is it normal to feel a change in energy when starting Flukolol?

Studies and official information indicate that fatigue (feeling tired or having low energy) is listed among the infrequent, or less common, adverse reactions documented during clinical trials. Any unexpected or severe symptoms should be communicated to the healthcare professional who prescribed the medicine.

Q: How quickly does Flukolol usually start to work?

According to the official product information, steady-state concentrations—the level needed for the drug to work consistently—are typically achieved within 5 to 10 days of once-daily dosing. When a loading dose is administered on the first day, the body's plasma concentrations can reach near steady-state levels by the second day.

Q: What happens if I forget to take Flukolol one day?

Official patient information describes that if a dose is missed, the general protocol involves taking the dose when remembered unless the next scheduled dose is too close, in which case the missed dose is omitted. The guidance is to avoid taking two doses at once.

Q: Does Flukolol need to be taken at a specific time of day?

The official instructions state that the oral formulation of Flukolol may be taken with or without food. This suggests flexibility in timing. Consistency in timing is a general practice with daily medicines, but the decision to set a routine time is made by the prescribing healthcare professional.

Q: Is it safe to drink alcohol while using Flukolol?

There are no known severe interactions with alcohol explicitly documented in the official labeling for a single dose. However, caution is generally advised because both the drug and alcohol can be processed by the liver. In some individuals, combining them may enhance the effects of alcohol or increase stress on the liver.

Q: Can I take Flukolol with my usual vitamin supplements?

Official product information notes that certain products containing polyvalent cations (such as supplements with iron, zinc, aluminum, or magnesium) can interfere with how Flukolol is absorbed. To minimize this effect, the official guidance states an advised time separation of 2 to 6 hours between taking these products and Flukolol.

Q: Is Flukolol suitable for people over the age of 65?

Official regulatory documents indicate that older adults are generally eligible for the drug's use. However, close monitoring and dose adjustments are necessary if the patient has renal impairment (reduced kidney function), as the body eliminates the medicine through the kidneys.

Q: Can Flukolol be used by children?

Use is established for pediatric patients who are four weeks of age or older for specific documented indications. Neonates (infants under four weeks old) also have defined dosing regimens with adjusted intervals due to their slower excretion rate.

Q: What are the official guidelines regarding Flukolol use during pregnancy?

The official label states that use is not recommended during the first trimester of pregnancy for non-life-threatening infections. Furthermore, high-dose, long-term use during pregnancy is strongly restricted due to the potential risk of fetal harm.

Q: Is Flukolol approved for use while breastfeeding?

Available evidence indicates the drug is excreted in breast milk at low levels. Official guidelines often consider the drug compatible with breastfeeding and generally advise against unnecessarily interrupting nursing.

Q: How long can a person typically expect to be on Flukolol?

Treatment duration is highly variable depending on the condition being treated. The length of time can range from a single dose for certain infections to extended therapy that may continue indefinitely for prevention of disease relapse, particularly in immunocompromised patients.

Q: Is it okay to stop taking Flukolol suddenly?

Official patient information describes the general expectation that the full course of medication be completed as prescribed. This protocol is defined to help prevent the risk of the condition returning.

Q: What should be done if an overdose of Flukolol is suspected?

Regulatory documents indicate that suspected overdose symptoms can include unusual effects such as hallucinations and paranoia. The regulatory protocol for a suspected overdose requires immediate medical attention or contact with emergency services.

Q: What happens in the body when Flukolol is working?

Flukolol works by creating a fungistatic activity within the fungal organism, which means it halts cell division and proliferation. It does this at a molecular level by blocking the production of ergosterol, a crucial structural component needed to maintain the integrity of the fungal cell membrane.

Q: Does Flukolol cause weight gain or weight loss?

Weight loss is mentioned in the official safety information as a potential symptom associated with rare but serious adverse reactions, specifically liver problems. It is not listed as a common, standalone side effect in the absence of other symptoms.

Q: What should I do if a minor side effect of Flukolol doesn't go away?

Patient information leaflets often state that the protocol for persistent or concerning side effects involves consultation with a healthcare provider.

Q: Is the mechanism of action for Flukolol fully understood?

The primary mechanism is defined in official documents as the selective inhibition of the fungal enzyme lanosterol 14alpha-demethylase. While this key action is well-defined, research is ongoing, and other mechanisms may be involved in the drug's overall effect.

Q: Why do some people report feeling [vague symptom, e.g., 'jittery'] after starting Flukolol?

Official documentation lists adverse reactions that affect the nervous and cardiovascular systems. These include infrequent side effects like dizziness, and in rare cases, cardiovascular events such as a fast or irregular heartbeat are reported, which may contribute to feelings of anxiety or 'jitters'.

Q: What evidence supports the use of Flukolol for its main purpose?

The regulatory approval and use of the drug are supported by findings from multiple randomized, controlled trials (RCTs). These studies have evaluated the drug’s effects on key clinical endpoints, including the rate of response and changes in clinical scores over specified treatment periods.

Q: Are there any long-term studies on children using Flukolol?

Clinical research findings have been published regarding the agent’s use in pediatric and adolescent populations. The primary goal of these studies was to assess clinical response and safety in younger patients.

Q: Is a follow-up appointment needed after starting Flukolol?

Official information indicates that for patients receiving prolonged therapy, monitoring of kidney, liver, and blood function may be required. This necessary monitoring and testing is typically managed through scheduled medical consultations.

Q: Do other medications need to be stopped when starting Flukolol?

The official label dictates that coadministration is contraindicated (must be avoided) with specific drugs known to dangerously prolong the heart's QT interval, such as cisapride or pimozide. In these cases, the other medication must be stopped.

Q: Where can I find the official regulatory documents for Flukolol?

Official documentation, such as the full Prescribing Information or Summary of Product Characteristics, is publicly available on the websites of regulatory bodies. These include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the NIH DailyMed.

Q: Does Flukolol affect a person's ability to drive?

Adverse reactions such as dizziness or, in rare cases, seizures, are documented. The existence of these documented risks is the reason for the official caution regarding driving or operating machinery.

Q: Can taking Flukolol cause changes in my sleep patterns?

Official documentation lists fatigue and, rarely, seizures among documented adverse reactions, which are known to impact sleep. While a direct change in sleep patterns is not explicitly listed, any central nervous system effect may indirectly affect sleep.

Q: What temperature should Flukolol be stored at?

Official regulatory labeling outlines specific storage conditions. Capsules and tablets must be stored at controlled room temperature, typically below 30 C (86 F). Liquid forms, including the IV solution and oral suspension, must be protected from freezing.

How should Flukolol be stored and disposed of?

How to Store and Dispose of Flukolol

Official regulatory labeling outlines specific storage conditions for Flukolol (Fluconazole) based on its dosage form. Flukolol capsules and tablets must be stored at controlled room temperature, typically below 30°C (86°F), and kept in their container with the lid tightly closed. Liquid forms, including the IV solution and reconstituted oral suspension, must be protected from freezing.

Stability and Child Safety

Once the oral suspension is reconstituted, any unused portion must be discarded after 14 days to maintain stability. A mandatory rule for all forms is to keep the medication out of the sight and reach of children.

Disposal

Expired or unneeded Flukolol must be disposed of according to FDA guidelines for safe drug disposal, and it should not be flushed down a toilet or poured down a drain. Any associated needles or sharps must be placed in an approved sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flukolol found in:

A-Z Index: